Article ; Online: Cost-Benefit Analysis of Hydrogen Breath Test-Directed Rifaximin for Treatment of Diarrhea-Predominant Irritable Bowel Syndrome.
2022 Volume 21, Issue 10, Page(s) 2695–2696.e1
MeSH term(s) | Humans ; Rifaximin ; Irritable Bowel Syndrome/complications ; Irritable Bowel Syndrome/drug therapy ; Cost-Benefit Analysis ; Diarrhea/drug therapy ; Breath Tests ; Hydrogen ; Rifamycins |
---|---|
Chemical Substances | Rifaximin (L36O5T016N) ; Hydrogen (7YNJ3PO35Z) ; Rifamycins |
Language | English |
Publishing date | 2022-09-22 |
Publishing country | United States |
Document type | Letter ; Research Support, Non-U.S. Gov't |
ZDB-ID | 2119789-1 |
ISSN | 1542-7714 ; 1542-3565 |
ISSN (online) | 1542-7714 |
ISSN | 1542-3565 |
DOI | 10.1016/j.cgh.2022.09.010 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 5836: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.